
Vaximm AG
Hochbergerstrasse 60C
4057 Basel
Switzerland
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.
info@vaximm.com | www.vaximm.com